Active	Status	Sponsor type	Region	Phase	Filter
14 Active 1 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Xu
NCT05664750: Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus	Completed	3	675	RoW	TNM002, Human tetanus immunoglobulin (HTIG)	Zhuhai Trinomab Pharmaceutical Co., Ltd.	Tetanus	03/23	07/23
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration	Active, not recruiting	3	488	RoW	BAT5906 injection, Lucentis	Bio-Thera Solutions	Neovascular (Wet) Age-related Macular Degeneration	04/24	06/25
Sun, Xiaonan
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease	Recruiting	3	400	RoW	SJP-0132, Placebo	Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd.	Dry Eye	07/25	08/25
Li, Peijun
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.	Completed	3	765	RoW	TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group	Vigonvita Life Sciences	Erectile Dysfunction	02/23	02/23
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration	Active, not recruiting	3	488	RoW	TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis	TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Neovascular Age-related Macular Degeneration	09/24	02/25
Gong, Lan
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease	Recruiting	3	400	RoW	SJP-0132, Placebo	Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd.	Dry Eye	07/25	08/25